MiMedx Group, Inc. has raised $150m in private equity and debt financing to scale commercialization of its advanced wound care products, marking a vote of confidence in the company’s new C-suite team.
MiMedx’s core business develops amniotic tissue products. The company uses a manufacturing process to transform human placental tissue into a variety of skin substitute products that promote skin healing for...